Session » Sjogren's Syndrome II: Insights into Pathophysiology

Meeting: 2014 ACR/ARHP Annual Meeting

Abstract Number: 2977

Distinct Serum Protein Signature and Novel Biomarkers of primary Sjogren’s Syndrome Revealed by comprehensive High-Throughput Proteomic Analysis

Abstract Number: 2978

Characterization of the Sjögren’s Syndrome Intergenic Non-Coding RNA 1 (SSINCR1)

Abstract Number: 2979

Nucleic Acid Sensing Receptors TLR7, RIG-I and MDA5 Collaborate in Driving the Systemic IFN Signature and Amplify the Pathogenic Loop: Potential New Targets for Therapy in Primary Sjogrens Syndrome

Abstract Number: 2980

Genome-Wide DNA Methylation Analysis of CD19+ B Cells in Primary Sjögren’s Syndrome

Abstract Number: 2981

Prognostic Value of the Complex P2X7 Receptor-Inflammasome in Patients with Primary Sjögren’s Syndrome at Lymphoma Risk

Abstract Number: 2982

Identification of Whole Blood Gene Expression Signature in Primary Sjögren’s Syndrome Associated Lymphoma

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.